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Medication event monitoring system
A B S T R A C T
Poor medication adherence remains frequent in schizophrenia. The present study examined the efficacy of two
month-long pilot interventions using the Medication Event Monitoring System (MEMS®). Thirty-three out-
patients at high risk for relapse were randomized to receive a smartphone-based intervention, a nurse-based
intervention, or treatment as usual. All patients then used the MEMS® to objectively measure medication ad-
herence over six months. No differences were observed in adherence measures or relapse rates across the three
groups. When using electronic medication monitoring as an objective measure of adherence, easily-implemented
interventions may not significantly improve adherence in patients at high risk for relapse.
1. Introduction
Medication non-adherence is prevalent in patients with schizo-
phrenia, highlighting the need for novel approaches to support patients
through frequent contact. In the goal of providing lower cost or easily-
implemented interventions, nurse-administered approaches have
shown positive results (Gray et al., 2004; Hudson et al., 2008), in-
cluding investigations using weekly or monthly telephone contact to
foster adherence (Montes et al., 2010; 2012). Autonomous smartphone-
based strategies have also demonstrated high feasibility and accept-
ability for patients with schizophrenia, as well as positive effects on
adherence rates (Kreyenbuhl et al., 2019; Velligan et al., 2013). How-
ever, previous findings have been based almost exclusively on self-re-
ported adherence that may bias evaluations of intervention efficacy
(Velligan et al., 2007). In particular, subjective evaluations of behavior
and experiences are frequently affected by memory biases, social de-
sirability and psychological states of the individual at the moment of
assessment (Baillet et al., 2016; Stone et al., 2003). Although electronic
medication event monitoring is regarded as a reliable and accurate
measure of adherence, few studies of schizophrenia have used such
devices when testing adherence strategies. Some researchers
(Velligan et al., 2013) using this approach reported significant im-
provements for patients receiving active interventions relative to
treatment as usual, but also included very frequent clinical monitoring
with additional interventions (every three days) if nonadherence con-
tinued. Information concerning the objective efficacy of less intensive
but perhaps more feasible interventions is currently lacking. The aim of
this controlled pilot study is to provide an initial comparison of
smartphone-based and nurse-based interventions in a sample of out-
patients with schizophrenia who are at high risk for relapse. All patients




Thirty-three outpatients were recruited from an ambulatory care
clinic in Bordeaux, France, from December 2014, to December 2016.
Inclusion criteria were a DSM-IV-TR diagnosis of schizophrenia or
schizoaffective disorder, high-risk relapse status (defined by a recent
hospitalization within the last two years), being at least 18 years of age,
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capable of understanding the study protocol, and treated with at least
one oral antipsychotic. If more than one antipsychotic was prescribed,
the principal antipsychotic was identified as the medication to be de-
livered using MEMS caps. Exclusion criteria were presence of comorbid
neurological diseases, mental retardation, or disability due to a serious
medical condition.
2.2. Procedures
The study was approved by the regional ethics committee and was
in accordance with the Declaration of Helsinki. All participants pro-
vided informed written consent prior to inclusion. The interventions
were designed to require low to moderate resources, thereby increasing
their feasibility in real-world clinical settings. They were administered
over a one-month period immediately after hospital discharge in light
of previous research using MEMS that demonstrated particularly poor
adherence during this period for patients at high relapse risk
(Misdrahi et al., 2018). Adherence and clinical outcomes were then
examined over a six month period in order to evaluate the potential
impact of the interventions beyond their immediate effects in the month
following hospital discharge. After baseline evaluations, participants
were informed of their computer-generated random assignment to one
of three study groups: a smartphone-based intervention (SI) developed
for this study that administered daily medication reminders for one
month asking whether or not the patient had taken his or her medi-
cations, and then provided automated supportive statements to en-
courage adherence on days of medication non-use (e.g. “taking your
medications today is important for your health and well-being”); Data
were extracted at the end of the study from smartphones dedicated to
this investigation; A manualized nurse-based intervention (NI) that
provided weekly telephone contact with patients for one month to
discuss potential barriers to medication use and to encourage ad-
herence; or treatment as usual (TAU) that did not provide additional
strategies to encourage adherence beyond baseline information. All
participants were trained to use MEMS caps that recorded the time and
date of each opening and closing of the bottle for a six-month period.
MEMS caps were refilled every month by the nurse, do not provide
reminders or alarms, and the MEMS data were not used in feedback to
patients.
Severity of schizophrenia and psychopathological variables were
also assessed using the PANSS (Kay et al., 1987) and the CGI-SCH
(Haro et al., 2003). Global functioning was assessed using the GAF scale
(DSMIV, 1995), insight regarding their illness with the SUMD
(Amador et al., 1991), and antipsychotic side-effects with the UKU
(Lingjaerde et al., 1987). Medication adherence using the MEMS® was
evaluated by medication taking compliance (TAC), correct dosing
(COD) and timing compliance (TIC) (see Misdrahi et al., 2018, for ad-
ditional information). Relapse was defined as psychiatric re-hospitali-
zation, and such events were recorded over the full six months of
follow-up.
2.3. Statistical analysis
Adherence data were analyzed using logistic models for longitudinal
binary data (Generalized Estimating Equations models). Due to the
small number of participants in each group and the non-normality of
data, we used the independent-sample Kruskal-Wallis test to compare
the ordinal variables between the 3 groups.
3. Results
The socio-demographic and clinical characteristics of the three
groups for baseline and follow-up assessments are summarized in
Table 1, as well as primary outcomes for medication adherence using
the MEMS caps. Participants differed only relative to age (p = 0.003)
with patients in the NI group being older. Seven patients did not return
the MEMS device or complete the follow-up appointment, and technical
problems with two additional devices precluded data extraction on
adherence. No differences were observed between these individuals and
the rest of the sample.
The average adherence using the MEMS caps was 59.8% over the
entire follow-up period. Among adherent patients, implementation was
high and consistent over time with 91.53% of patients taking their
medication as prescribed on any given day. The persistence measures,
which represent the length of time between initiation and treatment
discontinuation, decreased significantly over time in all groups and a
log-rank test found no significant difference in adherence between
groups (p = 0.295). In addition, no difference was observed at follow-
up concerning relapse rates for the three groups. At six months, two
patients were hospitalized in each of the TAU and SI groups and three
patients were hospitalized in the NI group.
4. Discussion
This study examined pilot interventions to manage adherence in a
sample of outpatients suffering from schizophrenia and at high risk for
relapse. The principal findings indicate that: (i) compared to TAU, the
two active interventions were not efficacious in significantly improving
medication adherence in patients at high risk for relapse; (ii) there was
a strong decrease in medication adherence over time in all study
groups. Despite the small numbers of participants that may preclude the
detection of certain effects, the mean adherence scores in the inter-
vention groups were very similar to patients receiving treatment as
usual over the six-month duration of the study and with no difference in
relapse rates.
These findings suggest that objective measures of adherence may
provide essential information that may differ from other studies
showing positive results based only on subjective reports by patients
(Misdrahi et al., 2018). Patient self-reports may be inaccurate due to a
range of factors including cognitive deficits, social desirability influ-
ences, and ecological momentary assessment investigations have ob-
served stark differences when comparing patient reports of the timing
of data collection compared to times recorded electronically
(Stone et al., 2003). Subjective evaluations of other daily experiences in
other populations, such concerning sleep quality and duration, have
also been shown to differ from objective measures as a function of the
intensity of momentary emotional states (Baillet et al., 2016). For these
reasons, populations known to have considerable cognitive and affec-
tive difficulties may be particularly prone to biases in personal eva-
luations of daily behaviors such as medication adherence.
The limitations of this pilot study include the restricted number of
participants and the short duration of the interventions. As such, the
findings should not be interpreted as providing a sufficient test of
specific interventions per se, rather than suggesting methodological
issues that should be considered in developing future clinical trials of
adherence. To our knowledge only one previous investigation demon-
strated positive effects for adherence interventions in this population
while using objective measures (Velligan et al., 2013), but it was based
on a sample with relatively high baseline adherence levels and that
utilized frequent clinical monitoring and additional interventions in
case of poor adherence.
Although considered the most reliable method available to measure
adherence, electronic monitoring of medication events is still an in-
direct measure of treatment adherence. It remains possible that a pa-
tient could open the pill container, but not take the prescribed dose.
However, it is unlikely that somebody would repeat this behavior over
the entire course of the study. We did not use additional methods to
check for extra openings nor self-report measures for adherence in these
patients. However, a staff nurse was charged with filling the MEMS caps
each month and recorded the remaining medication to reduce such
potential bias.
Interventions that are less intensive and more easily-implemented in
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community-dwelling samples may therefore require further develop-
ment to achieve efficacy, particularly among patients at high risk for
relapse. The promising findings observed for previous adherence in-
terventions should be pursued with a greater emphasis on new tools
that improve reporting accuracy.
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Table 1
Clinical characteristics of the three study groups at inclusion (M0) and follow-up (M6).
M0 M6
TAU N = 10 SI N = 12 NI N = 11 TAU N = 10 SI N = 12 NI N = 11
M SD M SD M SD p M SD M SD M SD p
Socio-demographic characteristics
Age (years) 36.30 5.50 30.67 7.66 47.55 12.41 <0.001 – – –
BMI (kg/m²) 24.82 5.22 25.57 6.32 28.67 6.98 0.329 25.98 7.04 25.52 4.36 28.78 3.30 0.553
Clinical variables
Illness duration (years) 7.10 6.30 9.41 7.04 16.27 12.23 0.062 – – – –
GAF score 48.75 8.45 58.45 16.64 50.50 13.43 0.260 – – – –
CGI-SCH score 3.25 1.04 2.73 1.35 3.60 0.97 0.232 3.25 1.71 2.00 1.22 3.00 1.00 0.336
PANSS positive score 17.22 4.35 15.73 4.80 18.80 6.05 0.404 14.50 5.32 13.60 4.77 14.20 2.59 0.949
PANSS negative score 17.44 5.46 15.36 6.30 18.30 6.34 0.529 17.25 4.27 17.20 4.66 16.00 3.94 0.880
PANSS general score 38.11 7.83 36.36 9.43 44.10 10.45 0.165 32.50 7.05 36.00 8.00 36.00 10.12 0.794
PANSS total score 72.78 13.89 67.45 16.36 81.20 19.97 0.197 64.25 14.43 66.80 16.38 66.20 15.16 0.968
SUMD score 8.11 4.46 7.55 3.88 7.90 4.07 0.953 – – – –
UKU score 10.44 13.14 6.64 3.35 7.10 4.77 0.529 6.00 4.08 5.20 2.77 6.20 4.32 0.908
4PAS score 35.60 6.77 37.17 5.08 34.64 4.90 0.554 34.75 6.85 33.40 7.70 37.40 5.03 0.635
Adherence variables
MEMS duration (days) – – – – 125.50 61.41 119.30 60.74 122.75 47.34 0.511
COD – – – – 76.74 25.79 80.69 13.42 82.88 20.93 0.750
TAC – – – – 89.63 14.84 91.28 12.30 93.78 21.18 0.622
TIC – – – – 65.73 34.33 70.07 21.93 70.89 31.59 0.813
SD: Standard Deviation; BMI: Body Mass Index; GAF: Global Assessment of Functioning; CGI-SCH: Clinical Global Impression-Schizophrenia; PANSS: Positive And
Negative Symptoms Scale for Schizophrenia; SUMD: Scale of Unawareness of Mental Disorder; UKU: Udvalg for Kliniske Undersogelser Side Effect Rating Scale;
4PAS: 4-Point ordinal Alliance Scale; COD: Correct adherence; TAC: Taking adherence; TIC: Timing adherence. Significant associations are in bold text.
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